Want to see HK:0455 full AI Analyst Report?
0455 Stock Chart & Stats
HK$0.13
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$0.13
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.08 - HK$0.22
Previous CloseN/A
Volume4.00K
Average Volume (3M)84.94K
Market Cap
HK$223.60M
Enterprise ValueHK$344.93
Total Cash (Recent Filing)HK$64.81M
Total Debt (Recent Filing)HK$132.66M
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Aug 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding2,150,041,700
10 Day Avg. Volume115,400
30 Day Avg. Volume84,945
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)0.61
Price to Sales (P/S)0.86
P/FCF Ratio99.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manageable LeverageModerate debt levels imply the company is not overburdened by fixed financing costs, preserving balance-sheet flexibility. Over a 2–6 month horizon this supports the ability to fund operations or small product investments without immediate refinancing stress if cash generation stabilizes.
Relatively Healthy Gross MarginsSustained gross margins in the low- to high-40s provide structural insulation for profitability if sales recover, giving room to absorb SG&A or R&D. This margin base enables more scalable operating leverage once top-line declines reverse.
Return To Positive Operating Cash FlowPositive operating and modest free cash flow in 2025 show the business can generate internal funding when functions align. If cash generation stabilizes, the company can reduce near-term external funding reliance and better support working capital and prioritized investments.
Bears Say
Persistent Net LossesWorsening net margins signal structural profitability pressure that erodes retained earnings and investor value. Over months this limits reinvestment capacity, risks further equity dilution if financing is required, and makes sustaining operations harder without a clear path to margin recovery.
Declining Revenue TrendA contracting top line reduces scale benefits and makes fixed-cost absorption more difficult, hindering margin recovery. Sustained revenue decline over multiple years raises structural questions about market positioning, product demand, or distribution effectiveness.
Volatile Cash Generation And Prior Deep FCF DeficitsHistoric swings and multi-year negative free cash flow create execution and funding risk: reliance on external capital or asset sales may be necessary if positive 2025 cash flow proves temporary, raising refinancing and strategic flexibility concerns over the medium term.
Tianda Pharmaceuticals Ltd. News
0455 FAQ
What was Tianda Pharmaceuticals Ltd.’s price range in the past 12 months?
Tianda Pharmaceuticals Ltd. lowest stock price was HK$0.08 and its highest was HK$0.21 in the past 12 months.
What is Tianda Pharmaceuticals Ltd.’s market cap?
Tianda Pharmaceuticals Ltd.’s market cap is HK$223.60M.
When is Tianda Pharmaceuticals Ltd.’s upcoming earnings report date?
Tianda Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 10, 2026 which is in 9 days.
How were Tianda Pharmaceuticals Ltd.’s earnings last quarter?
Tianda Pharmaceuticals Ltd. released its earnings results on Mar 26, 2026. The company reported -HK$0.017 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Tianda Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Tianda Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Tianda Pharmaceuticals Ltd. pay dividends?
Tianda Pharmaceuticals Ltd. pays a N/A dividend of HK$0.003 which represents an annual dividend yield of N/A. See more information on Tianda Pharmaceuticals Ltd. dividends here
What is Tianda Pharmaceuticals Ltd.’s EPS estimate?
Tianda Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tianda Pharmaceuticals Ltd. have?
Tianda Pharmaceuticals Ltd. has 2,150,041,700 shares outstanding.
What happened to Tianda Pharmaceuticals Ltd.’s price movement after its last earnings report?
Tianda Pharmaceuticals Ltd. reported an EPS of -HK$0.017 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Tianda Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in HK:0455
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tianda Pharmaceuticals Ltd.
Founded in 1992 and headquartered in Central, Hong Kong, Tianda Pharmaceuticals Limited operates as an investment holding company and a subsidiary of Tianda Group Limited. The firm, which changed its name from Tianda Holdings Limited in September 2012, focuses on the research, development, manufacturing, and distribution of a wide array of pharmaceutical, biotechnology, and healthcare products. Its commercial reach extends across Mainland China, Hong Kong, and Australia. The company's diverse portfolio includes traditional Chinese medicines, chemical drugs, biological products, and medical appliances. These offerings target numerous therapeutic areas, such as cardio-cerebrovascular health, pediatric care, anti-flu and respiratory conditions, anti-infection, detoxification, and urological disorders. Health supplements are specifically marketed under the "Herb Valley" and "Tuokang" brand names. Furthermore, Tianda Pharmaceuticals is involved in the wholesale and retail of Chinese herbal medicines, traditional Chinese medicine (TCM) decoction pieces, and other Chinese medicinal products, provides Chinese medical services, and trades agricultural by-products.
Technical Analysis
Extrawell Pharmaceutical Holdings Limited
―
Wai Yuen Tong Medicine Holdings Limited
―
PuraPharm Corp. Ltd.
―
Dawnrays Pharmaceutical Holdings Ltd.
―
Pak Fah Yeow International Limited
―